Integrin Alpha-2 as a Potential Prognostic and Predictive Biomarker for Patients With Lower-Grade Glioma.

Diffuse gliomas are the most common malignant brain tumors with the highest mortality and recurrence rate in adults. Integrin alpha-2 (ITGA2) is participated in a series of biological processes, including cell adhesion, stemness regulation, angiogenesis, and immune/blood cell functions. The role of ITGA2 in lower-grade gliomas (LGGs) is not well defined. Firstly, we downloaded RNA-sequencing and relevant clinical information from The Cancer Genome Atlas (TCGA) cohort, The Chinese Glioma Genome Atlas (CGGA) cohort and The anti-PD-L1 (IMvigor210)the related immune cohorts. Next, prognosis analysis, difference analysis, clinical model construction, enrichment analysis and immune infiltration analysis are performed for this study. These analyses indicated ITGA2 may have clinical application value and research value in LGG immunotherapy. We also detected the mRNA and protein expression of ITGA2 in three LGG cell lines and normal glial cells using quantitative real-time polymerase chain reaction assay (qRT-PCR) and western blot assay (WB). Our study not only offers a novel target for LGG immunotherapy, but also can better comprehend the mechanism of the development and progression of patients with LGG. This study revealed that ITGA2 may be a potential prognostic and predictive biomarker for LGG, which can bring new insights into targeted immunotherapy.